IGM Biosciences Debt 2024

IGM Biosciences Aktienanalyse

What does IGM Biosciences do?

IGM Biosciences Inc was founded in 2010 in Mountain View, California. It is a biopharmaceutical company focused on the development and commercialization of immunotherapy products for the treatment of cancer. Their business model is based on the use of proprietary technology platform to produce high-quality and high-quantity antibody products. The company has different business areas including research and development, antibody production and testing, and marketing and distribution of their products. They offer a wide range of products such as monoclonal antibodies, multi-specific antibodies, and antibody constructs. Their history began with the development of their platform technology, which allows for the production of antibodies with modified properties. This has led to breakthrough products for the treatment of cancer. One of their main products is IGM-2323, a multi-specific antibody targeting solid tumors. It works by binding to two different targets on the cancer cell simultaneously and activating the immune system to destroy the cancer cell. Another important product is IGM-8444, an antibody construct targeting B-cell lymphomas. It has been designed to enhance the immune response to cancer cells by specifically binding to a surface protein on the cancer cells. IGM Biosciences Inc has also formed partnerships with other companies to collaborate on the development of new products. For example, they have partnered with GlaxoSmithKline (GSK) to develop a new class of multi-specific antibodies for the treatment of cancer. Overall, IGM Biosciences Inc has a strong track record and continues to have significant growth potential in the future. Their business model is based on leveraging their proprietary technology platform to develop innovative immunotherapy products for cancer. With a wide range of products and partnerships in the pipeline, it is likely that this company will continue to be successful in the future. IGM Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding IGM Biosciences's Debt Structure

IGM Biosciences's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing IGM Biosciences's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to IGM Biosciences’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in IGM Biosciences’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about IGM Biosciences stock

What is the debt of IGM Biosciences this year?

IGM Biosciences has a debt level of -112.52 USD this year.

What was the debt of IGM Biosciences compared to the previous year?

The debt of IGM Biosciences has increased by -7.16% compared to the previous year dropped.

What are the consequences of high debt for investors in IGM Biosciences?

High debt can pose a risk for investors of IGM Biosciences, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of IGM Biosciences?

Low debt means that IGM Biosciences has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from IGM Biosciences affect the company?

An increase in debt of IGM Biosciences can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of IGM Biosciences affect the company?

A reduction in debt of IGM Biosciences can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of IGM Biosciences?

Some factors that can influence the debt of IGM Biosciences include investments, acquisitions, operating costs, and revenue development.

Why are the debts of IGM Biosciences so important for investors?

The debts of IGM Biosciences are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can IGM Biosciences take to change the debt?

To change the debt, IGM Biosciences can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does IGM Biosciences pay?

Over the past 12 months, IGM Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IGM Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of IGM Biosciences?

The current dividend yield of IGM Biosciences is .

When does IGM Biosciences pay dividends?

IGM Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IGM Biosciences?

IGM Biosciences paid dividends every year for the past 0 years.

What is the dividend of IGM Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IGM Biosciences located?

IGM Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von IGM Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IGM Biosciences from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did IGM Biosciences pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of IGM Biosciences in the year 2023?

In the year 2023, IGM Biosciences distributed 0 USD as dividends.

In which currency does IGM Biosciences pay out the dividend?

The dividends of IGM Biosciences are distributed in USD.